Living+ Peptides news https://livingpluspeptides.com/news/ Dated FDA, DEA and WADA actions that affect peptides, with primary sources. en-us Wed, 28 Oct 2026 00:00:00 GMT HHS interim policy covers 6 peptides for compounding https://livingpluspeptides.com/news/hhs-interim-peptide-compounding-policy/ https://livingpluspeptides.com/news/hhs-interim-peptide-compounding-policy/ Wed, 28 Oct 2026 00:00:00 GMT On Oct 28, 2026 HHS said it will not act against 503A compounding of BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 under conditions. Not FDA approval. WADA 2027 List names peptides as S0 examples https://livingpluspeptides.com/news/wada-2027-prohibited-list-peptides/ https://livingpluspeptides.com/news/wada-2027-prohibited-list-peptides/ Mon, 26 Oct 2026 00:00:00 GMT WADA published its 2027 Prohibited List in September 2026, in force January 1, 2027. S0 now names peptides as examples. GLP-1 status is unchanged. FDA advisers review seven peptides for compounding https://livingpluspeptides.com/news/pcac-july-2026-peptides/ https://livingpluspeptides.com/news/pcac-july-2026-peptides/ Mon, 26 Oct 2026 00:00:00 GMT FDA's compounding advisers met July 23-24, 2026 on BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon. FDA staff proposed against all seven. FDA proposes keeping GLP-1s off the 503B bulks list https://livingpluspeptides.com/news/glp1-503b-bulks-list-proposal/ https://livingpluspeptides.com/news/glp1-503b-bulks-list-proposal/ Mon, 26 Oct 2026 00:00:00 GMT A May 1, 2026 FDA notice proposes leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list. Comments closed July 30, 2026. Most peptides leave FDA's Category 2 list https://livingpluspeptides.com/news/fda-category-2-peptides-withdrawn-2026/ https://livingpluspeptides.com/news/fda-category-2-peptides-withdrawn-2026/ Mon, 26 Oct 2026 00:00:00 GMT FDA's Category 2 list now names only kisspeptin-10 and ibutamoren from this site. BPC-157, TB-500 and others left after nominators withdrew. FDA warns 30 telehealth firms over compounded GLP-1 ads https://livingpluspeptides.com/news/fda-warns-telehealth-compounded-glp1/ https://livingpluspeptides.com/news/fda-warns-telehealth-compounded-glp1/ Mon, 26 Oct 2026 00:00:00 GMT On March 3, 2026, FDA announced 30 warning letters to telehealth firms over claims that compounded GLP-1s match approved drugs or hide who makes them. DEA telemedicine flexibilities run through 2026 https://livingpluspeptides.com/news/dea-telemedicine-extension-2026/ https://livingpluspeptides.com/news/dea-telemedicine-extension-2026/ Mon, 26 Oct 2026 00:00:00 GMT DEA and HHS extended telemedicine prescribing of controlled medications through December 31, 2026. None of the peptides on this site is DEA controlled.